AAMDC

Across TCGA pan-cancer cohorts, AAMDC mass-spec protein is linked to patient survival in 6 of 34 cancer types, making it a survival-associated AAMDC data layer compared with 22 for mass-spec protein and 1 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher AAMDC mass-spec protein is associated with better overall survival. In most high-consensus cancer types, elevated AAMDC expression acts as an unfavorable survival marker, although some lineages such as PDAC show a favorable association.

PDAC, HNSC, and LSCC are the cancer types where AAMDC mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Median	III,IV	0.968	0.331	<.001	26	view →
HNSC	DFS	Median	All	0.262	0.818	.012	14	view →
LSCC	DFS	Median	II,III,IV	0.500	0.832	.002	12	view →
CCRCC	DFS	Quartile	All	0.570	0.919	.009	8	view →
UCEC	OS	Quartile	All	0.864	1.000	.036	8	view →
LUAD	DFS	Tertile	III,IV	0.471	0.962	.031	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

AAMDC–PDAC (OS)

Open the PDAC breakdown →